We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,812

Mixed Results: Federal Circuit’s Intervening 101 Determination Faces PTAB Dissent
  • McDermott Will & Emery
  • USA
  • March 27 2017

After the US Court of Appeals for the Federal Circuit addressed the very same issue and patent, the Patent Trial and Appeal Board (PTAB) reached a


Factual Findings Required to Show “Apparent Reason to Combine”
  • McDermott Will & Emery
  • USA
  • March 27 2017

Addressing issues of obviousness and anticipation in the context of an inter partes review, the US Court of Appeals for the Federal Circuit issued


Section 101: Protecting Software & Other Technologies
  • McDermott Will & Emery
  • USA
  • March 23 2017

Section 101 of the patent statute provides a fundamental threshold for the types of inventions that can be patented. In this episode, McDermott IP


Secondary Considerations of Non-Obviousness Cap on Obviousness Showing
  • McDermott Will & Emery
  • USA
  • February 28 2017

In a rare case where secondary considerations of non-obviousness carried the day, the Patent Trial and Appeal Board (PTAB) concluded that even though


Wrong Inventor Defense Fails in Pharmaceutical Litigation
  • McDermott Will & Emery
  • USA
  • February 27 2017

Addressing derivation and obviousness issues, the US Court of Appeals for the Federal Circuit affirmed the district court's denial of a generic drug


Multiple Actors May Perform Steps in Method Claims for Purposes of Inducement
  • McDermott Will & Emery
  • USA
  • February 27 2017

Addressing the issue of divided infringement, the US Court of Appeals for the Federal Circuit affirmed the district court's finding of induced


Electronic Trading Claims Are Patent Eligible
  • McDermott Will & Emery
  • USA
  • February 27 2017

The US Court of Appeals for the Federal Circuit affirmed a district court's holding that claims directed to electronic trading are patent eligible


Sovereign Immunity Can Shield State University Research Foundations in PTAB Proceedings
  • McDermott Will & Emery
  • USA
  • February 27 2017

Addressing the application of the sovereign immunity defense under the 11th Amendment in the inter partes review (IPR) context, the Patent Trial and


Preliminary Injunction Maintained Despite Adverse Decision in Parallel Post-Grant Review
  • McDermott Will & Emery
  • USA
  • February 27 2017

Addressing the merits of an injunction in a case where the district court and the Patent Trial and Appeal Board (PTAB) disagreed as to the validity


Article III Injury-in-Fact Required to Appeal PTAB Final Written Decision in IPR
  • McDermott Will & Emery
  • USA
  • February 27 2017

Addressing the legal standard for demonstrating standing in an appeal from a final agency decision, the US Court of Appeals for the Federal Circuit